Torsdag 11 December | 10:37:13 Europe / Stockholm
Svenska | English

Newbury Pharmaceuticals

Filter arrow-icon
År arrow-icon
Typ arrow-icon
Språk arrow-icon
Rensa
Se endast PM som skrivits på följande språk
Se endast PM som skrivits från valt år
Se endast PM som skrivits på följande språk
2025-12-09 16:15:00 Kallelse till årsstämma i Newbury Pharmaceuticals AB 1,46 SEK | 0,00%  | 0,00 MSEK pdf download
2025-11-18 13:50:00 Nordic Market Update 1,55 SEK | +6,16%  | 0,29 MSEK pdf download
2025-11-11 13:15:00 Newbury Pharmaceuticals appoints its founder Karl Karlsson as new CEO 2,00 SEK | +1,78%  | 0,02 MSEK pdf download
2025-10-29 08:00:00 Newbury Pharmaceuticals year-end report September 2024 – August 2025 2,11 SEK | -14,23%  | 0,22 MSEK pdf download
2025-10-24 08:30:00 Newbury Pharmaceuticals Secures Generic Approval for Mirtazapin Newbury 2,47 SEK | +2,07%  | 0,06 MSEK pdf download
2025-10-23 14:30:00 Newbury Pharmaceuticals Secures Generic Approval for Ivermectin Newbury 2,42 SEK | +4,76%  | 0,09 MSEK pdf download
2025-08-11 10:00:00 Newbury Pharmaceuticals Secures Generic Approval for Melatonin Newbury 2,64 SEK | -1,49%  | 0,12 MSEK pdf download
2025-07-09 08:00:00 Newbury Pharmaceuticals interim report September 2024 – May 2025 2,82 SEK | -7,24%  | 0,23 MSEK pdf download
2025-04-16 13:30:00 Newbury Pharmaceuticals Secures Generic Approval for Pazopanib Newbury 3,36 SEK | -0,30%  | 0,08 MSEK pdf download
2025-04-09 08:00:00 Newbury Pharmaceuticals interim report September 2024 – February 2025 3,34 SEK | -1,18%  | 0,05 MSEK pdf download
2025-03-19 11:00:00 Newbury Pharmaceuticals expands its portfolio with four new products 3,38 SEK | +1,20%  | 0,02 MSEK pdf download
2025-03-14 08:30:00 Newbury Pharmaceuticals Secures Approval for Macitentan film-coated tablets 3,34 SEK | +2,45%  | 0,06 MSEK pdf download
2025-01-24 10:00:00 Newbury Pharmaceuticals Secures Generic Approval for Pomalidomide capsules 3,48 SEK | -2,25%  | 0,25 MSEK pdf download
2025-01-24 08:00:00 Newbury Pharmaceuticals interim report September 2024 – November 2024 3,48 SEK | -2,25%  | 0,25 MSEK pdf download
2025-01-22 09:00:00 Newbury Pharmaceuticals Secures Generic Approval for Bosutinib tablets 3,54 SEK | +0,57%  | 0,07 MSEK pdf download
2025-01-15 11:23:00 ANNUAL GENERAL MEETING OF SHAREHOLDERS IN NEWBURY PHARMACEUTICALS AB 3,46 SEK | +1,76%  | 0,17 MSEK pdf download
2024-12-11 19:30:00 Newbury Pharmaceuticals publishes its annual report for 2023/2024 3,62 SEK | +3,43%  | 0,01 MSEK pdf download
2024-12-11 09:30:00 Kallelse till årsstämma i Newbury Pharmaceuticals AB 3,50 SEK | -3,31%  | 0,00 MSEK pdf download
2024-10-28 10:00:00 Newbury Pharmaceuticals Secures Generic Approval for Buspiron 4,00 SEK | +3,09%  | 0,40 MSEK pdf download
2024-10-23 11:15:00 Newbury Pharmaceuticals year-end report September 2023 – August 2024 3,78 SEK | -4,55%  | 0,34 MSEK pdf download
2024-09-27 15:56:00 Strong Quarterly Sales Announcement from Newbury Pharmaceuticals 3,66 SEK | +10,91%  | 0,33 MSEK pdf download
2024-09-23 13:00:00 Newbury Pharmaceuticals Secures Approval for Varenicline in Sweden 3,18 SEK | +5,30%  | 0,24 MSEK pdf download
2024-09-13 11:30:00 Regulatory Filing for Teduglutide 3,26 SEK | +5,16%  | 0,25 MSEK pdf download
2024-07-31 10:04:00 Extraordinary general meeting in Newbury Pharmaceuticals AB (publ) 3,70 SEK | +5,11%  | 0,11 MSEK pdf download
2024-07-12 09:30:00 NOTICE OF EXTRAORDINARY GENERAL MEETING IN NEWBURY PHARMACEUTICALS AB 3,30 SEK | -2,37%  | 0,01 MSEK pdf download pdf download pdf download
2024-07-10 08:00:00 Newbury Pharmaceuticals interim report September 2023 – May 2024 3,26 SEK | -6,86%  | 0,14 MSEK pdf download
2024-06-18 08:45:00 Newbury Pharmaceuticals is strengthening its portfolio with Dalbavancin Powder 3,28 SEK | +1,86%  | 0,04 MSEK pdf download
2024-04-10 08:00:00 Newbury Pharmaceuticals interim report September 2023 – February 2024 3,41 SEK | -2,29%  | 0,13 MSEK pdf download
2024-01-17 10:00:00 Nintedanib Newbury approved by the Swedish Health Authorities 3,75 SEK | +1,63%  | 0,09 MSEK pdf download
2024-01-10 11:20:00 ANNUAL GENERAL MEETING OF SHAREHOLDERS IN NEWBURY PHARMACEUTICALS AB 3,67 SEK | +16,51%  | 0,61 MSEK pdf download
2024-01-10 08:00:00 Newbury Pharmaceuticals interim report September 2023 – November 2023 3,67 SEK | +16,51%  | 0,61 MSEK pdf download
2023-12-13 23:00:00 Newbury Pharmaceuticals publishes its annual report for 2022/2023 3,79 SEK | +1,88%  | 0,12 MSEK pdf download
2023-12-08 13:00:00 Kallelse till årsstämma i Newbury Pharmaceuticals AB 3,64 SEK | +3,41%  | 0,04 MSEK pdf download
2023-10-11 08:00:00 Newbury Pharmaceuticals year-end report September 2022 – August 2023 3,32 SEK | +1,53%  | 0,09 MSEK pdf download
2023-09-18 14:00:00 Newbury Pharmaceuticals AB has successfully signed a 15 MSEK loan agreement 3,91 SEK | +1,56%  | 0,11 MSEK pdf download
2023-07-19 11:30:00 Desmopressin Newbury approved by the Swedish Health Authorities 3,23 SEK | +5,90%  | 0,22 MSEK pdf download
Enter your email address and you will get a mail for verification you subscription to content on this page and filter


Select the time zone location for site wide time

Europe
London
Oslo
Stockholm
Helsinki

America
New York / Eastern
Chicago / Central
Los Angeles / Western

Ett mail har skickats till den givna adressen. För att logga in, klicka på "Login" i mailet för att verifiera ditt konto

Företag

Pressmeddelanden